Lord Moylan : To ask His Majesty's Government what treatments exist for those mantle cell lymphoma patients unable to access allogeneic stem cell transplants due to (1) ethnicity, (2) age, and (3) ethnicity and age. Parliamentary Under Secretary of State, Department of Health and Social Care (Lady Merron) : A number of National Health Service treatment options are available for patients with mantle cell lymphoma, and may include: - chemotherapy plus rituximab; - autologous s

Lord Moylan : To ask His Majesty's Government what safeguards exist to prevent patients from losing access to established, life-extending cancer treatments as a result of changes to NICE methodology. Parliamentary Under Secretary of State, Department of Health and Social Care (Lady Merron) : The National Institute for Health and Care Excellence (NICE) evaluates all newly licensed cancer medicines and may recommend promising treatments for use through the Cancer Drugs Fund (C

Lord Moylan : To ask His Majesty's Government what assessment they have made of the impact on patients of withdrawing access to an existing cancer treatment, namely CAR-T therapy for relapsed or refractory mantle cell lymphoma, which has been available on the NHS since 2021. Lord Moylan : To ask His Majesty's Government how many patients have received CAR-T therapy for mantle cell lymphoma via the Cancer Drugs Fund; and what assessment has been made of the clinical outcomes f

Lord Moylan : To ask His Majesty's Government what assessment they have made of the availability of specialist rail plant used in the maintenance of the rail network. Minister of State, Department for Transport (Lord Hendy of Richmond Hill, CBE) : Network Rail is responsible for assessing the availability of specialist rail plant used in maintaining the rail network. It is currently reviewing its long-term equipment requirements for track maintenance and renewals, to ensure t